Directory of Peptide API Manufacturing Plants

Grand Pharmaceutical Group Limited (Hong Kong stock code 00512.HK), with a history dating back to 1939, is a technologically innovative international pharmaceutical company headquartered in Wuhan. Its business covers nuclear drug anti-tumor diagnosis and treatment, cardiovascular and cerebrovascular precision interventional diagnosis and treatment, respiratory and critical care, five senses, cardiovascular and cerebrovascular first aid, API plates and high-quality amino acids. The Group has 8 R&D centers around the world, more than 770 R&D personnel, and more than 133 research projects. It continues to promote the "Go Global" global innovation strategy and in-depth cooperation with innovative pharmaceutical products and scientific research institutions in the United States, Australia, Germany, Belgium and other countries. Its business segment includes the "API segment" and "high-quality amino acids". However, the official website mainly focuses on the fields of nuclear drugs, cardiovascular and cerebrovascular interventions, mRNA and other innovative pharmaceutical devices, and does not specifically introduce polypeptide APIs.

Wuhan Yuelai Health Industry Co., Ltd. (hereinafter referred to as Yuelai, twinklife) was founded in 2014 with a registered capital of 120 million yuan. It is a health industry enterprise oriented towards the cause of anti-aging. The company attaches importance to the research and development of polypeptides. It has set up a number of research units such as a polypeptide anti-aging laboratory, a polypeptide basic laboratory, a polypeptide functional application laboratory, a polypeptide product testing laboratory, and a polypeptide cytology laboratory. In 2019, it jointly established the "Anti-aging Nutrition and Health Research Center" with the China Health Promotion Foundation, Huazhong University of Science and Technology Tongji Medical College, and Hubei Provincial Center for Disease Control and Prevention. In 2021, it built a smart factory integrating intelligence, standardization, Internetization, etc. It is equipped with a 100,000-level GMP purification production workshop, with powder and liquid drinking bags as the production core. In 2024, its manufacturing plate Hubei Yuehai Biotechnology Co., Ltd., in conjunction with China Ocean University, Nanchang University and other units, issued the first "Collagen Tripeptide" group standard in China. The business covers health food, health food, cosmetics and personal care products. The products have passed CMA, CNAS, FDA and other certifications, serving more than 1 million consumers. Note: It is mainly based on the R&D and application of peptide health foods/cosmetics, and is not a large-scale API API API manufacturer.

Wuhan Newtop Biotech Co., Ltd., located in Wuhan, Hubei, is a pharmaceutical manufacturing enterprise integrating R&D, production, sales and service, focusing on organic chemistry and pharmaceutical chemistry, with its own R&D center and laboratory. The company mainly focuses on polypeptides and pharmaceutical raw materials, including Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, GHK-Cu, Melanotan, Thymosin alpha-1, LL-37, Selank, Epitalon, etc., and provides peptide freeze-dried powder and raw materials. With peptide synthesis, purification and active ingredient separation capabilities, the production system has obtained GMP, ISO 9001, HSE and other quality certifications, and has a D-level (ISO 8)/C-level (ISO 7) clean workshop; products are mainly exported to Europe, the United Kingdom, the United States, Canada, Australia and other countries and regions.

Wuhan Vanz Pharm Inc.), located in Wuhan, Hubei Province, was established in 2011 (some B2B files are recorded as 2016). It is a API (API), pharmaceutical intermediates, fine chemicals, peptides and food additives that integrate R&D, production and sales. Its products are sold worldwide. The company has a R&D center of about 1000 square meters in Wuhan (including multiple synthesis laboratories, pilot amplification laboratories and analytical laboratories). The manufacturing base is equipped with 100L-5000L reactors, which can provide one-stop services from R&D to commercial production. With long-term cooperation from Shanghai Institute of Organic Chemistry and Wuhan University, it has completed more than 20 APIs and intermediates R&D. Business covers custom synthesis (CDMO/CMC orientation), API contract production, quality control and regulatory consulting. Note: The company uses small molecule APIs/intermediates and custom synthesis as its core business, and peptides is only one of its product categories, not a dedicated peptide API factory.

Wuhan Tiantianhao Biological Products Co., Ltd. has been deeply engaged in the health industry for more than 30 years, focusing on polypeptide technology, integrating raw material production, product research and development, intelligent manufacturing and global sales, and positioning "functional peptide global business application leader" and "peptide national standard setting enterprise". The company was formerly known as Wuhan Peptide Research Institute, which was founded in 1997; in 2008, it presided over the preparation of China's first national standard for polypeptide products, "Soybean Peptide Powder" (GB/T 22492-2008). The company has built Wuhan Peptide Research Institute and Provincial Peptide Engineering Technology Research Center, built a provincial engineering technology research center with Wuhan Light Industry University, and established a postgraduate training base with Wuhan University, forming a whole chain innovation system from basic research to the transformation of achievements. Peptide raw products include microbial peptides, plant peptides (soybean peptides, walnut peptides, corn oligopeptides, flaxseed peptides, rice peptides, etc.), animal peptides (collagen tripeptides, fish collagen peptides, albumin peptides, casein peptides, whey peptides, etc.), and "peptide components". A total of more than 100 invention patents have been applied for, more than 200 SCI/scientific papers have been published, and the products have served 170 million consumers worldwide. It has been certified by ISO9001, ISO22000, halal, FDA, SC and other systems, and has China Peptide Industrial Park ("Most Beautiful Factory"), using AI intelligent screening and live cell targeting technology to prepare high-purity functional peptides.

Wuhan Sanyang Kaitai Biotechnology Co., Ltd., located in Wuhan City, Hubei Province, was established in 2018 and is a biotechnology enterprise focusing on peptide synthesis, antibody preparation and protein expression. The company relies on the technical experience of the core team (each core member has been engaged in the industry for more than 10 years) to provide cost-effective scientific research service solutions for scientific research institutions and corporate customers. The core business includes: customized peptide synthesis (peptides of different lengths, amino acid sequences and purity levels can be synthesized according to customer requirements, and accompanied by HPLC and MS test reports), protein expression (prokaryotic/eukaryotic expression system, from gene synthesis, vector construction to purification one-stop), antibody preparation (high specificity, high affinity antibodies), and biological testing services such as ELISA and Western Blot. The company has peptide synthesis, purification, freeze-drying equipment and perfect process, which can be delivered in 3 days at the earliest, and is positioned as a high-tech scientific research service company. Note: Mainly research-grade customized peptide/antibody/protein services, not a large-scale production enterprise of API API APIs, and API certification such as GMP/DMF has not been seen.

Wuhan Renfukang Pharmaceutical Co., Ltd. was established in January 2016 with a registered capital of 150 million yuan. It is a subsidiary of the listed company Renfu Pharmaceutical Group (600079.SH) and a technology-based small and medium-sized enterprise. It is located in Wuhan East Lake New Technology Development Zone. The company is mainly engaged in drug production and research and development. It has four dosage form production lines: tablets, hard capsules, lyophilized powder injections and injections. In 2017, it obtained a drug production license and GMP approval for clinical drugs. In August 2019, it passed the FDA on-site audit and obtained FDA certification. As an open pharmaceutical preparation CMO/CDMO/mAh service platform, it focuses on the commissioned development and production of preparations (especially injection small batch clinical samples, orphan drugs, and precious concentrates), and provides integrated services at home and abroad from raw materials to formulations, clinical, BE, registration, and production.

Wuhan Moore Biotechnology Co., Ltd. was established in 2008 with a registered capital of 21.4824 million yuan. It is a high-tech enterprise specializing in the research and development of peptide biological new drugs. It is a national "double" project construction unit and a high-tech enterprise in Hubei Province. It has built the "Moore Biology — Wuhan University Active Substance Research and Development Center" and academician expert workstation. It has obtained more than 20 national invention patents and has undertaken 2 major national major new drug creation science and technology projects. The company has established a full-chain peptide drug research and development platform (peptide gene engineering expression/purification, molecular screening design and target research, biologic drug identification and analysis, new preparations, etc.), equipped with 180 sets of high-end equipment. By the end of 2025, it will put into production a 14,500 ㎡ digital GMP genetic engineering production platform and cell production platform that meets the requirements of GMP in China, the United States, and Europe. It can produce 200kg of simaglutide API and other genetically engineered peptide products annually, and is being inspected by the Hubei Provincial Pharmaceutical Administration for drug production licenses. Products include Simiglutide APIs and backbone, liraglutide, HPV-BVTAG protein, HBV-PreS1 protein, and engineering enzymes; provide CDMO customization services (mg to kg) such as molecular screening, design, expression, purification, identification, process development, and quality control of polypeptide drugs.

Leading Hitech (Wuhan) Co., Ltd.) is a private company located in Wuhan that provides import and export services such as modern agriculture, feed and food additives, and health nutrition raw materials. The entrepreneurial team has been in the industry for nearly 20 years and has obtained the agency rights of many well-known brands in China. The related products have FAMI-QS, GMP +, HACCP, ISO22000 and other certificates, which meet European and American standards. Products include functional lipids (glyceryl tributyrate, etc.), vegetable essential oils, preservatives, sweeteners, as well as micro-ecological, polysaccharides and other functional additives (Bacillus licheniformis, glutathione, L-carnitine, DHA&EPA, etc.), and provide international trade services such as factory audits, global procurement distribution, formulation and production.

Wuhan Jiuan Pharmaceutical Co., Ltd. was founded in 1951 (originally Wuhan No.2 Pharmaceutical Factory) and renamed in 1999. It is a high-tech enterprise that mainly produces generic drugs and integrates R&D, production and sales. It is located in Wuhan Pharmaceutical Industrial Park on the shore of Lake Thomson in Jiangxia District, Wuhan City. The company has built a large-volume, small-volume injection and pre-perfusion-sealed injection workshop that meets the GMP standards. It has more than 140 drug approval numbers (more than 150 in a word). The core products are clinical emergency rescue drugs (such as dopamine hydrochloride injection, dexamethasone sodium phosphate injection, magnesium sulfate injection, etc.). Many varieties are included in the national emergency rescue drug catalogue.

Wuhan Hualong Biopharmaceutical Co., Ltd., formerly known as Wuhan Meishan Biochemical Pharmaceutical Factory established in 1985, was restructured into the current company in 2000. It is a high-tech pharmaceutical enterprise integrating R&D, production and sales. It has more than 300 employees (more than 200 professional and technical personnel at colleges and above, and 36 practicing pharmacists). The company focuses on the field of injection drugs, especially bio-peptide products, and is one of the top three biochemical pharmaceutical companies in the country. The annual production capacity is about 90 million units. In 2004, it passed the GMP certification as a whole. In 2020, it was certified as a "high-tech enterprise" and won the bid for centralized procurement of national drugs in 2023. The core products of polypeptides include terlipressin injection, thymosin/thymosin injection for injection, somatostatin for injection, bone peptide injection, transfer factor injection, etc., covering cardiovascular and cerebrovascular, immune, digestive and other systemic therapeutic drugs.

Wuhan Huadong Biotechnology Co., Ltd. was founded on June 28, 2011 by Dr. Zeng Jianhua of Tongji Medical College of Huazhong University of Science and Technology. It is a high-tech enterprise with Dr. as the core team. Relying on Tongji Medical College of Huazhong University of Science and Technology, Wuhan Biotechnology Research Institute and other institutions, it is committed to the research, development, production and sales of anti-aging pharmaceuticals, functional foods, diagnostic kits and innovative biological drugs. The company has a number of national patents and registered trademarks (including patents in the fields of preventing white hair and skin aging), has independently developed a world-class anti-aging active ingredient "reduced MSR", and has completed a 10 million yuan angel round of financing, and has built a provincial-level university-enterprise joint key laboratory with Hubei Second Normal College. Its "Huapeptide" brand products feature peptide active ingredients, but are generally positioned as anti-aging cosmetics and functional health products companies.

Wuhan Jiushengtang Biotechnology Co., Ltd. (Peptide Valley Jiushengtang) is a company specializing in the research, development, production and sales of bioactive peptides. It is known as the "originator" of bioactive peptides in China and the first company in China to realize the transformation, industrialization and industrialization of bioactive peptides. The company was founded by Zou Yuandong, "the father of Chinese peptides" and "the father of enzymatic polypeptides", with "enzymatic polypeptides" as the core technology, focusing on new peptide immunological agents such as 39-peptide peptides (oral liquid), and has 39-peptide US/Japanese patents, as well as a number of peptide patents such as wheat protein peptide, camellia seed protein peptide, walnut protein peptide, bitter melon polypeptide, and puerarinide. The company has built a production base in Wuhan Jiushengtang, positioning peptide industry pioneers, covering bioactive peptide (enzymatic peptide) raw materials and functional health products, and setting up a peptide museum and other popular science exhibitions.

Wuhan Hubei Huntide Biotech Co., Ltd.), an innovative manufacturer of small molecule peptides under Jetide Health, is located in Wuhan Optical Valley Biocity and has a production base built according to industrial standards in Xintan Industrial Park, Wuhan Economic Development Zone. The company's team has an average of more than 10 years of experience in the pharmaceutical/biological field. It has built a peptide R&D center of about 800 ㎡ and a cGMP standard multi-function workshop, focusing on the synthesis of small peptides with 2–6 amino acids. The core technologies include liquid phase, solid phase, fragment and enzyme catalytic synthesis (especially liquid phase synthesis), and provide modification services such as C-terminal/N-terminal modification, disulfide bond/amide cyclization. Products range from polypeptide building blocks, intermediates to active/functional peptides and peptide derivatives (such as carnosine L-Carnosine, glutamine dipeptide, N-acetyl carnosine, Gly-His-Lys skin care peptide, etc.), and provide process development, custom synthesis, and OEM foundry (laboratory/pilot to commercial scale) for customers in the pharmaceutical, cosmetic, and food sectors. The parent company Jipeptide Biotechnology (founded in Wuhan in September 2012) has 200 acres of chemical land, 20,000 square meters of self-built plant, 4 industrialized production lines, and an annual production capacity of 1,000 tons of small molecule peptides, fully implementing GMP management.

Founded in 1998 and listed on the Shenzhen Stock Exchange (300199) in 2011, Hybio Pharmaceutical is one of the earliest listed peptide drug companies in China. It is a national high-tech enterprise, focusing on the research and development, production and marketing of peptide drugs and small nucleic acid drugs, and layout of "innovative drugs + generic drugs" and CRDMO services. The company has a national-level platform such as the "National Local Joint Engineering Laboratory of Peptide Drugs", undertakes a number of national projects, and has won the second prize of the National Technology Invention Award and other honors. The quality system has passed multi-country GMP/cGMP certification such as China NMPA, US FDA, EU EMA, Brazil ANVISA, Australia TGA, Indonesia BPOM, South Korea MFDS. The Wuhan subsidiary (Linkong Demonstration Park in Huangpi District) is a special API production base for polypeptides. It is designed and built in accordance with international cGMP standards and equipped with a fully automatic polypeptide synthesis and purification system. It has passed the official GMP certification of China/the United States/Australia, and is expanding its API production line, with the goal of building a world-class polypeptide API base. The peptide API has now been sold to more than 20 countries and regions, and the preparation has been sold to more than 90 countries and regions. It has cooperated with international pharmaceutical companies such as Ferring, Hikma, and 3SBio Mandi, and has been first imitated/approved by the FDA in the United States.

Founded in 1992 (initiated by seven shareholders such as Wuhan University in 2000) and listed on the gem of the Shenzhen Stock Exchange on August 8, 2017 (stock code: 300683), Wuhan Haite Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise targeting biologically innovative drugs. The main business is the production, sales, import and export of bioengineering products and freeze-dried powder injections. There are 25 existing production codes for biological products and chemical drugs, and more than 1,000 employees (76% of whom have a college degree or above). The company's park covers an area of 138,000 square meters, has a production plant that meets the GMP standard of 14,800 square meters, and has passed the national GMP certification. It has five technology platforms such as a postdoctoral workstation and a "Hubei Provincial Rare Disease Drug Engineering Technology Research Center". The product focuses on the nervous system and oncology field, and has been listed on the national market as a class I biologic new drug for injection of mouse nerve growth factor NGF (Jinluojie, nerve growth factor is a polypeptide) and a class of genetically engineered biologic new drug for injection of epnemine (CPT). The company also provides CRO/CMO/CDMO technical services to domestic and foreign pharmaceutical companies, covering peptide immunomodulatory and enhancement drugs, APIs and intermediates, and expanding in the fields of macromolecules, small molecule drugs and in vitro diagnostics.

Wuhan sqn Biotechnology Co., Ltd. claims to be a leading supplier of chemical raw materials and peptides in China, focusing on health peptides, beauty/cosmetic peptides and active raw materials. It claims to have a GMP factory and 15 years of supply experience. Its products are mainly weight loss, beauty, and anti-aging peptides (such as Smeglutide, Telpotin, GHK-Cu, Melanotan II, nad +, DSIP, SS-31, etc.). It provides OEM/ODM and customization, and relies on the global logistics network to sell to North America, Europe, Southeast Asia and other markets. Note: According to the enterprise information of the Made-in-China platform, the company is registered as a "Trading Company". It was established in 2024, with a scale of 1–49 people, a registered capital of 100,000 yuan, and no independent official domain name. It mainly conducts business through the B2B platform. Its GMP qualification and "manufacturer" positioning need to be carefully verified.

Founded in 2000, Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical Co., Ltd. is a high-tech enterprise and enterprise technology center in Jiangsu Province. The company's new industrial base has been completed and put into operation in Jiangsu Changshu New Material Industrial Park. It is planned to be built according to the high standards of the pharmaceutical industry at home and abroad, and is the core carrier for the integration of polypeptide and small molecule drug research and development and commercial production. Representative peptide/polypeptide preparation products include: cortisol ® terlipressin for injection, Amgas ® octreotide acetate injection, Anqi ® carbetocin injection, lidine ® thymus method for injection, etc. The base can meet the needs of capacity upgrades and business development, and provide reliable products and professional technology solutions for domestic and foreign pharmaceutical partners. (Note: Group subordinates contain a small amount of non-pharmaceutical sectors such as hotels, etc., which have been omitted.)

Klein (stock code 002821) is a leading CDMO serving global pharmaceutical and biotechnology companies with more than 25 years of industry experience, 8 R&D and manufacturing sites, and 9,700 + employees (including 4,600 + R&D scientists). Its Chemical Macromolecules Division (CMMD) provides polypeptide CDMO services covering traditional polypeptides, pseudopeptides, peptide + linkers, peptide drug conjugates (PDCs), polymer-drug conjugates, and highly active peptide molecules. 400 + peptide project experience has been accumulated, which can produce linear/cyclic peptides of up to 40 amino acids (containing disulfide bonds, book peptides/thioether cyclic peptides), supports the SPPs/LPPS/heterozygous fragment strategy and modifications such as peg, lipidation, and N-methylation, and provides full-process GMP peptide production, release and stability research, and IND/NDA document support from preclinical to NDA declaration verification. The project covers GLP-1, antiviral, antibacterial, anti-tumor, macular degeneration and other fields. The company passed 65 + successful inspections by FDA, NMPA, TGA, MFDs, etc.

Sinopep-Allsino Biopharmaceutical is a global commercial API provider and full-service CDMO focused on end-to-end CMC development and commercial production of peptides, oligonucleotides and small molecule APIs. Serving global innovative pharmaceutical companies since 2009, it has passed four US FDA inspections and strictly follows FDA and ich guidelines. The peptide production capacity reaches 20–30 metric tons per year; a large-scale GMP oligonucleotide base has been built in Lianyungang, Jiangsu Province (annual output can reach thousands of kilograms, containing ASO, siRNA, GalNAc, AOC, liposomes and other conjugates). Services cover polypeptide/oligonucleotide CDMO, FTE, discovery services, generic APIs and preparations (oral solid preparations, lyophilized powder injections, etc.), providing process development, analytical method development and validation, stability research, and IND/NDA regulatory support to achieve a seamless connection from early development to commercial supply.

Teide Pharmaceutical (Zhejiang) Co., Ltd. (stock code 03880.HK) is a contract research, development and production organization (CRDMO) specializing in polypeptides, providing full-cycle services from early discovery, pre-clinical, clinical development to commercial production. Headquartered in Hangzhou, China, it has commercial production bases and offices in China and the United States, and has been deeply engaged in the field of polypeptides for more than 20 years. Provides CRO (polypeptide new chemical molecular entity discovery synthesis) and CDMO (polypeptide CMC development and commercial production) services, and has extended to oligonucleotide CDMO since 2021. It has provided more than 1,000 customers worldwide with support for the synthesis, development, production and CMC declaration of polypeptides that meet the regulatory requirements of major markets around the world. The project covers more than 50 countries such as China, the United States, Japan, Europe, South Korea and Australia. Clients include large pharmaceutical companies, biotech companies, virtual pharmaceuticals and start-ups. The peptide biochemical tirpopeptide drug substance in the subsidiary has completed the US FDA DMF registration.

PharmaMing Kangde (stock code 603259.SH/2359.HK) is a leading global contract research, development and production (CRDMO) company with operations in Asia, Europe and North America, serving more than 6,000 partners in more than 30 countries around the world. Its WuXi tides platform focuses on one-stop CRDMO services for APIs and formulations of oligonucleotides, polypeptides and related chemically coupled drugs, covering the entire lifecycle from drug discovery to commercialization. The polypeptide manufacturing base is located in Changzhou and Taixing, Jiangsu: The Changzhou base has more than 20 polypeptide production lines, and the total volume of solid phase polypeptide synthesis (SPPs) reactors after integration with Taixing has exceeded 41,000 liters (32,000 liters after expansion in 2024, 100,000 liters at the end of 2025, and planned to expand to 130,000 liters). In 2023, it supports about 50 preclinical to commercial polypeptide projects, delivering more than 15 tons of polypeptide APIs and intermediates. The Changzhou base has passed regulatory inspections by the FDA in the United States, NMPA in China, PMDA in Japan, MFDs in South Korea, and ANVISA in Brazil many times.

Chongqing Zhixia Chemical Co., Ltd. (related to Nanjing Chenruisheng Biomedical Technology) was established in September 2023. It is a small and micro enterprise, mainly engaged in the research and development and supply of polypeptide GLP-1 raw materials, representing products including Semaglutide, Tirzepatide and other polypeptide raw materials. The business model is factory, customization and service, and the products are mostly marked as "for scientific research or export only". The company announced a registered capital of 500,000 yuan, 10–50 employees, and an annual turnover of about 3-5 million yuan. The contact information is shared with Nanjing Chen Ruisheng (the same phone/email address), and is positioned as a peptide small molecule GLP-1 raw material supplier for the global scientific research and export market.

High-volume foreign trade foundries with stable purity ≥ 98%

Sinopeptide Biochemical Co., Ltd. is a wholly owned subsidiary of Tide Pharmaceutical (03880.HK). Founded in 2001, it is headquartered in Hangzhou, China. Its international headquarters is located in California, USA. It has commercial production bases and offices in China and the United States. The company specializes in contract research, development and production (CRDMO) of polypeptides and oligonucleotides, providing full-cycle services from early discovery, pre-clinical, clinical development to commercial production; extending CDMO capabilities to the oligonucleotide field since 2021. Deeply cultivating polypeptides for more than 20 years, we have provided more than 1,000 customers around the world with support for the development, production and CMC declaration of polypeptides that meet international regulatory standards. The projects cover more than 50 countries and regions such as China, the United States, Japan, Europe, Korea, and Australia, with a total of 300 + CDMO projects and 13 CMO projects. A team of peptide/oligonucleotide experts with the ability to produce challenging molecules from simple to complex. The peptide biochemical tirpopeptide drug substance in the subsidiary has completed the US FDA DMF registration.

Zhejiang Peptide Biotechnology Co., Ltd. (a national-level specialized and new key "small giant" enterprise) focuses on the research and development, production and application of polypeptides. It has a national post-doctoral scientific research station, Shaoxing academician expert workstation and provincial enterprise research institute. It is the first polypeptide synthesis engineering research center in Zhejiang Province. It has obtained 108 relevant invention patents and is one of the domestic leaders in the large-scale production of polypeptides. The company builds a "one main two-wing, two-wheel drive" strategy: mainly pharmaceutical polypeptides and technical services, and cosmetic polypeptides and other polypeptides are two wings. The product line includes more than 60 kinds of peptide APIs, covering obesity, diabetes, gastrointestinal diseases and other fields. Many core products have been filed/approved in many countries; more than 40 kinds of cosmetic peptide raw materials cover anti-wrinkle, anti-aging, repair, whitening and so on. The production system has passed FDA certification in the United States and has been certified by halal, EcoVadis, ISO and other management systems. With large-scale production capacity: the annual output of polypeptide powder is 8000kg, and the annual output of polypeptide bulk solution is 2000t. Products are exported to the United States, the European Union, Canada, South Korea, Japan, Russia, etc., and establish stable cooperation with internationally renowned companies.

Conscientia Industrial is a core member of the Conscientia Group, headquartered in China, focusing on the R&D, manufacturing and global marketing of high-quality APIs (APIs), peptides, nutritional ingredients, cosmetic ingredients and fine chemicals. Its manufacturing facilities and products comply with international standards such as GMP and ISO, and its APIs strictly comply with USP, BP, EP, JP, KP, CP and other pharmacopoeial requirements. In the field of peptides, the company provides high-purity peptide synthesis and supply. The products cover hundreds of peptides such as α-Casozepine, AOD-9604, BPC-157, CJC-1295, GHK-Cu, GLP-1 (smectin, tilapopeptide, liraglutide, mazdopeptide, retalutide, etc.), beauty and scientific research peptides, all of which have been verified by HPLC with purity of 98% +. The supply is stable and supports rapid global shipments. It is positioned to provide peptides and raw materials for the global life science and chemical industries.

ZhuoShang Bio/ExcelBio is a GMP-certified nutraceutical manufacturer founded in 2013, located in Luoyang, Henan Province, focusing on providing one-stop OEM/ODM solutions for global brands; with 30,000 m ² of FDA-registered factories (10 production lines with an annual output value of more than $100 million), supporting a minimum order of 500 pieces. Main proteins, polypeptides and custom peptides (such as GHK-Cu, GHK-Cu powder, etc.), protein powder, gummies, capsules, beverages, etc., provide full link services from R&D, procurement, production to logistics, and hold GMP, FDA, COA, HACCP, Halal and other certifications. Note: The company's self-built official website has not been retrieved. This profile is from the Made-in-China corporate store, which is a third-party trading platform information, for reference only.

Xi 'an Huilin Biotechnology Co., Ltd. ("Xi 'an Huilin Biotechnology", established in about 2006/2012, Xi 'an, about 15 years) is committed to the field of natural raw materials, building a diversified matrix across biochemical synthesis, high content of monomers, plant-derived extracts, medicinal and food homology and large health products, and providing one-stop raw material solutions for multiple industries. In terms of polypeptides, the product center covers acetyl tetrapeptide-2, zinc pyroglutamate, etc., and also manages cosmetic/cosmetic peptide raw materials (such as acetyl hexapeptide-8, blue copper peptide, etc.). It supports both sampling and customization/mass production lines, emphasizing the traceability of the whole process of raw materials and multi-dimensional quality control. According to third-party platform information, it has ISO 9001/14001/13485, FSSC 22000, halal and other certifications.

Suzhou Nike Tai Biotechnology Co., Ltd. (Suzhou) is an innovative biotechnology enterprise focusing on innovative research and development and customized production of polypeptides. Relying on advanced synthetic technology platform and strict quality management system, it provides high-purity, high-quality polypeptide raw materials and integrated solutions from milligrams to kilograms in the fields of medicine, skin care and health. The main business covers peptides/cosmetic peptides/pharmaceutical peptides: the field of peptide raw materials provides bioactive peptides (scientific research, diagnostics, pharmaceutical intermediates); cosmetic peptides focus on active peptides such as anti-aging, repair, and firming; pharmaceutical peptides focus on research and development and process development of highly difficult pharmaceutical peptides, providing innovative drug and generic drug companies with one-stop CMC services from preclinical to commercialization. Equipped with a modern R&D center and GMP-compliant production facilities, we aim to be a reliable partner in the field of peptide technology.

Sichuan Tongsheng Biomedical Co., Ltd. (founded in 2011, Deyang) is committed to providing key starting materials (KSM) and intermediates for polypeptide drugs and chemical drugs. The products cover the screening, small trials, pilot trials to commercial production services of key materials for clinical new drugs, including polypeptide drugs KSM, Fmoc-amino acids, unnatural amino acids, polypeptide side chains, short peptides, and small molecular drugs KSM, Boc-amino acids, amino acid derivatives, and heterocyclic pharmaceutical intermediates. The company has a number of 50-5000L reactor multi-functional production lines (grams to 100 tons), R&D team of 30 people (including 2 doctorate, 6 master's), QC/QA of nearly 30 people; currently planning to build about 65 acres of new base (including GMP workshop, three multi-functional workshop and peptide protection amino acid line workshop), has provided custom synthesis services for the world's leading pharmaceutical companies, CDMO and API companies.

Sichuan Tongsheng Amino Acid Co., Ltd. (established in 2003 and located in Deyang, Sichuan) is committed to the research and production of amino acids and their derivatives, polypeptides and derivatives. Its products are exported to the international markets such as the United States, the United Kingdom, Italy, France, Germany, India, and Japan. In 2011, it was awarded the title of a high-tech enterprise. In 2016, it was licensed as an academician expert workstation for the production of amino acid food additives. In strict accordance with ISO9001: 2008 and GMP management specifications, it implements USP, EP, AJI, JP and other industry standards. Its products are based on amino acids, polypeptides and derivatives.

Shenzhen Xingkaiyue Biotechnology Co., Ltd. (established in 2020, Shenzhen) official website "About Us" positions it as a comprehensive technology enterprise integrating R&D, production and sales, mainly engaged in fine chemicals, chemical synthetic raw materials, pharmaceutical intermediates, chemical preservatives, fragrances, food additives, etc. The company profile on the official website does not take peptides/peptide APIs as the core business direction (third-party platforms show that they also deal in oat peptides, silk amino acids and other cosmetic raw materials), and the overall trade is mainly in fine chemicals and pharmaceutical intermediates.

Sichuan Pengting Technology Co., Ltd. (founded in 2021, Sichuan) is positioned as a core value creator in the global peptide industry chain, focusing on the research and development, customization and industrial-scale production of high-value APIs and cosmetic peptides. Integrated supply chain and 6,500 ㎡ co-production base, products cover metabolic APIs (Tirzepatide, Semaglutide, Retatrutide, etc.) and popular cosmetic raw materials (GHK-Cu blue copper peptide, Melanotan-II, etc.). With ISO/GMP dual certification, we can provide a full set of DMF, COA and MSDS documents. The R&D team includes 5 + PhDs, and has industrialized more than 100 effective raw materials. We support 50g trial orders to tonnage commercial supply, with a delivery period of 15–30 days. Customers cover biotechnology innovation pharmaceutical companies, CDMOs, cosmetic brands and scientific research institutions in North America, Europe and Asia.

Sichuan Ampelbo Biotechnology Co., Ltd. (Chengdu Boke Pharmaceutical Technology Co., Ltd., Chengdu) is a professional R&D, production and sales of amino acid derivatives (amino alcohols, amino aldehydes, N-methyl amino acids, amino acid tert-butyl esters, Boc/Fmoc/Cbz protected amino acids, benzyl esters, amino acid amides, etc.). It also provides polypeptides, piperidine derivatives and chiral amine series products. It can provide domestic and foreign customers with high-quality pharmaceutical intermediates and fine chemicals from grams, kilograms to tons. Its products are exported to Europe and North America. It is a small high-tech/trade-oriented enterprise (with a staff size of about 8–50 people). The polypeptide is one of its product lines, with a partial amino acid protecting group and a polypeptide side chain/intermediate direction.

Shenzhen Peptide Chuangsheng Technology Co., Ltd. is a pioneer supplier of high-quality active peptides (cosmetic peptides) based in Shenzhen and radiating the world. It focuses on molecular biology and AI-driven peptide structure-activity research to provide efficient, verifiable and sustainable active peptide raw material solutions for scientific research institutions, pharmaceutical groups, medical cosmetic institutions and functional skin care brands. It has a Peptide AI design system and a peptide professional-grade laboratory, with a raw material purity of 99.8% pharmaceutical grade, adopts a biological + chemical synthesis green process (zero solvent instead of DMF), and a transdermal rate of > 80%, which meets the EU ECOCERT, US FDA gras, Japan JHOSPA and other regulations; and provides customized peptide synthesis (minimum order of 100g, 3–6 weeks delivery). The product covers 100 cosmetic peptides with 9 major efficacy matrices (blue copper peptide GHK-Cu, acetylhexapeptide-8/aquirelin, palmitoyl pentapeptide-4, conopeptide, etc.), 100% made in China, and serves 100 + customers worldwide (European pharmaceutical giant, North American pure beauty brand, CJK head beauty group).

Shenzhen Jianxiang Biotechnology (JYMed/Jianyuan Pharmaceutical) is a CDMO enterprise specializing in polypeptides, providing polypeptide API R&D and GMP production from milligrams to tons. With 13 cGMP production lines and 85,000 L spps/LPPS reactor volumes, the Hubei base has an annual production capacity of 10 + tons and has passed FDA, NMPA, and EDQM inspections. Employees of 650 + are located in Shenzhen (7,000 ㎡ R&D center), Hubei (52,000 ㎡ API production base, OEB-5 isolation), and Shenzhen (formulation FDF base). Services cover custom synthesis, polypeptide API manufacturing (long chain, unnatural amino acids, conjugates), cosmetics/veterinary drugs/health peptides and CDMO, supporting 1 g R&D to 100 kg commercial batches. With 20 + years of experience in peptide chemistry and CDMO, we provide peptide intermediates, APIs and CDMO services to pharmaceutical companies worldwide.

Shenzhen Han Yu Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange, 300199, listed in 2011) is a national high-tech enterprise specializing in the R&D, production and sales of polypeptide drugs and small nucleic acids. Founded in 1998, it is an early listed polypeptide drug enterprise in China. The company has built a national and local joint engineering laboratory for polypeptide drugs, a national public experimental center for innovative polypeptide drugs, and a national pilot technology platform for the preparation of polypeptide drugs. It has undertaken a number of national-level projects and won the second prize of the National Technology Invention Award. It has passed the GMP/cGMP certification in China, the United States, the European Union, Brazil, Australia, South Korea and other countries, and has four major production bases: Shenzhen Pingshan Preparation Base, Wuhan Peptide Featured API Base (through the China/United States/Australia GMP certification, which is being expanded), Gansu Chengji Pharmaceutical Intermediates Base, Yunnan Dali Industrial Hemp Base, etc., to open up the whole chain control from raw materials to drugs. The APIs are sold to 20 + countries and regions, and the preparations are sold to 90 + countries and regions. The polypeptide products include GLP-1 injections such as liraglutide, smeclutide, tirpotide, etc., atoxiban, etibapeptide, etc., and have CRDMO (custom R&D + custom production) capabilities. The monomer reactor capacity is 100L-10000L.

Founded in 2018, it focuses on the European, American, Indian, and African markets, and supports Paypal, Western Union, and Bitcoin payments.

Main overseas small peptide brand OEM

Shanghai QYAOBIO Co., Ltd. (ChinaPeptides/QYAOBIO), founded in October 2008, is a technology-based enterprise focusing on peptide synthesis, protein expression, and antibody preparation. In China, peptide solid phase synthesis (SPPs) technology was adopted earlier. The company maturely mastered 300 + peptide special modification core technologies, and has branches and scientific research laboratories in Suzhou, Wuhan, and Ezhou; cumulatively serving more than 50,000 customers worldwide, covering more than 50 countries and China's Hong Kong, Macao, and Taiwan regions, of which more than 90% are biomedical research institutions and pharmaceutical companies such as universities, hospitals, laboratories, and research institutes. Has passed ISO 9001: 2015 quality system certification, > 99% peptide synthesis success rate, provide HPLC/MS report and optional endotoxin/salt type test, as soon as 3 days delivery; core business is peptide synthesis, protein expression and antibody preparation.

Shanghai Chutin Biotechnology Co., Ltd. (official website www.apeptides.com) is a high-tech enterprise that mainly uses polypeptides, supplemented by amino acids, fluorescent dyes, carbohydrate derivatives, and small molecules for custom synthesis. Main polypeptide custom synthesis (ordinary linear peptide mg-kg grade, purity up to 99%; complex modified peptide such as glycopeptide, lipid peptide, phosphate peptide, cyclic peptide, fluorescent label peptide, biotin label peptide, complex antigen peptide map, etc.), protein cross-linking (KLH/BSA/ova), catalog peptide and characteristic peptide library (RGD peptide library, Amyloid peptide library, drug peptide library, antimicrobial peptide library, etc.), protein expression, ELISA kit, stable isotope labeled polypeptide (¹ C/² N) and small molecule custom synthesis. The company type is mainly trade/technical service, and the team size is about 11–50 people.

Shanghai Bootech Biotechnology Co., Ltd. (registered as "Bootech" on the official website, and the user is recorded as "Botech") was founded in 2003 and is a technology company specializing in the synthesis of peptides and the sale of supporting reagents. The company relies on and absorbs international advanced technology, has advanced synthesis and purification equipment, and develops a complete set of peptide synthesis routes, which can provide peptide products of various sizes and requirements (mg to kg). Each polypeptide is accompanied by HPLC analysis and mass spectrometry identification report. Provided by a number of senior researchers/professors to provide process guidance, long-term cooperation with domestic and foreign pharmaceutical companies and scientific research institutions to provide high-quality peptides and peptide raw materials products at a price advantage.

Focus on overseas Biohacking channels, mature composite peptide kits

Shaanxi TNJONE Pharmaceutical Co., Ltd.) has been deeply engaged in the field of pharmaceutical raw materials for more than ten years. It is a high-tech enterprise integrating scientific research, production and sales. It has a GMP-compliant API factory in Huxian, Shaanxi. The company focuses on customized peptide and intermediate products. API meets CP, USP, BP, EP pharmacopoeial standards and supports third-party testing and certification. It is equipped with advanced analysis, concentration, purification, lyophilization and synthesis equipment. It has a professional QA/QC team and provides OEM/ODM customization services. Cumulative service 300 + customers, export 50 countries, R & D personnel 30 +. Peptide products include Tirzepatide, Retatrutide, cosmetic peptides (such as GHK-Cu, Palmitoyl Tetrapeptide-7), etc., while operating plant extracts.

Shaanxi Borui Xiangtai Pharmaceutical Co., Ltd. was established on February 25, 2022 with a registered capital of 5 million yuan and is located in Lianhu District, Xi 'an City. It is an innovative enterprise specializing in the R&D, production and sales of polypeptides and their derivatives. The company uses "amino acid synthesis peptide APIs, personalized precision medical customized peptides, biochemical extraction products and multi-component biochemical drugs" as its product positioning; the representative varieties of synthetic peptides include thymosin acetate, oxytocin, nootropic peptide, temorelin, sermorelin, tilbopeptide, retarutide, lanrein, triplelin, liraglutide, etc. According to the chemical platform information, the company is relatively small (1–10 employees, 1–5 R&D), mainly engaged in Retatrutide, TB500, BPC157, etc., and does not have an official website.

Headquartered in Shanghai and founded in Zhangjiang in 1998, GL Biochem is a leading international scale manufacturer of protected amino acids, peptides and antibodies, led by a team of doctoral experts at home and abroad. The company has 8 production bases and 3 R&D centers around the world, with a construction area of about 45,000 square meters. Equipped with advanced equipment such as 400MHz nuclear magnetic resonance, mass spectrometer, amino acid analyzer, multi-channel/microwave peptide synthesizer, and more than 200 analytical/preparative HPLC, it produces more than 10,000 peptides per month, accounting for more than 60% of the global research peptide market. For more than 20 years, he has filed more than 70 Chinese invention patents and published 20 papers in the field of peptides. In 2008, he acquired an antibody company and in 2011, he acquired an Australian company, MIMOTOPES, with a sales service network covering the world. Products include customer peptides, catalog peptides, drug peptides, cosmetic peptides and Fmoc/Boc/Z amino acids, unnatural amino acids, etc.

Qingdao Sigma Chemical Co., Ltd.) mainly develops, manufactures and sells pharmaceutical raw materials, chemical intermediates, biochemicals, veterinary drugs and nutritional products, with synthetic capacity ranging from grams to tons, and provides custom synthesis and contract production (CMO). Peptides are one of its product lines. The official website lists GHRP-6, CJC-1295, Melanotan, HGH Frag 176-191, Ipamorelin, Hexarelin, PT-141 and other peptide raw materials, and claims to have a professional production quality control team, domestic and foreign warehousing and global shipping channels.

Frontier Biopharmaceutical (Nanjing) Co., Ltd. was established in 2013 and landed on the Science and Technology Innovation Board (688221.SH) of the Shanghai Stock Exchange in October 2020. It is a national specialized new "small giant" enterprise and a national high-tech enterprise. The company focuses on the R&D, production and sales of innovative drugs that do not meet major clinical needs, and has established a complete system covering molecular design, pharmaceutical research, clinical, registration, large-scale production and quality control. The technology platform includes three major directions: long-acting polypeptides, small nucleic acids, and high-end generic drugs/patches; its independently developed national class 1 anti-HIV new drug, albuvirtide ® (the world's first long-acting HIV-1 fusion inhibitor), was approved for marketing in 2018. The company has built high-end green APIs and preparations production bases in Jiangning, Nanjing and Qihe, Shandong in line with China's NMPA, US FDA and EU EMA standards to serve the global market. In 2024, the production base passed the FDA on-site inspection with "zero defects", and the Nanjing formulation base passed the GMP compliance inspection.

Nanjing Yuanpeptide Biotechnology Co., Ltd. (Yuanpeptide Biotechnology) was established in 2018 and is located in the Biomedical Valley/Zhongdan Ecological Life Science Industrial Park in Jiangbei New District of Nanjing. It is a science and technology-based small and medium-sized enterprise (selected as a science and technology-based small and medium-sized enterprise in Jiangsu Province in 2025) that focuses on the synthesis of scientific research peptides and customized services. The company has 46 employees, an independent research and development center and 900 square meters of sterile laboratory, 4 standardized peptide production lines, equipped with Waters LC-MS/MS, UPLC, automatic purification system, automatic lyophilization system and other precision instruments, with a peak monthly production capacity of about 3000 peptides. Stable synthesis of conventional linear peptides and 60 amino acid long peptides, 100 amino acid super long peptides, specializing in polydithiocyclic peptides, head and tail closed-loop peptides, book peptides, highly hydrophobic membrane penetrating peptides, D-type amino acid peptides, glycopeptides, lipopeptides and other complex structures; modified types cover phosphorylation, sulfonation, methylation, acetylation, pegylation, biotin labels, a variety of fluorescent labels (FITC/Cy series), isotope labels (13c/15N), protein cross-linking and more than 300 kinds. Service ranges from milligrams to kilograms, and long-term cooperation with universities and medical institutions such as Nanjing University, Fudan, Shanghai Jiaotong University, and West China Hospital.

Founded in 2023, Nanjing Peptide Research Biotechnology Co., Ltd. is located in Nanjing Jiangbei New District New Material Industrial Park. It is a high-tech enterprise specializing in the research and development, production, sales and transfer of polypeptide products. The company has 200 square meters of office space, 900 square meters of standardized laboratory, equipped with Agilent LC-MS, ultra-high-pressure liquid chromatography, freeze-dryer, ultraviolet spectrophotometer and other precision instruments, with full chain production, research and development, testing capabilities; the team has an average experience of more than 7 years in the field of polypeptide production and research. Main polypeptide synthesis (mg to kg, purity crude to > 98%), polypeptide modification (fluorescent labeling, disulfide/amide bonding/book peptide looping, peg modification, unnatural amino acids, etc., more than 300 kinds of modification and continuous increase), catalog polypeptide (more than 1000 kinds in stock and continuous increase), and protective amino acids (g to kg, tonnage amplification). Adhering to the concept of "integrity, rigor, and pragmatism", we provide customized peptide synthesis services for universities and research institutes at home and abroad.

Founded in 2021, Motif Biotech is located in Suzhou High-tech Zone. In March 2023, the peptide R&D and production base was completed and put into production. Motif Biotech is an innovative peptide CRDMO enterprise focusing on the customization, R&D, production and service of peptide-related products. Motif Biotech is committed to becoming an international platform integrating peptide scientific research and customization, drug peptide intermediates and impurity customization, peptide API production, drug peptide R&D and process development, and beauty peptide R&D and production. The factory building of Suzhou headquarters is about 4,300 square meters, with multiple R&D and production workshops, more than 100 synthesis/purification/analysis laboratories, and a planned total annual raw material production capacity of 30 kg (powder). The GMP workshop was designed and constructed according to ich Q7, and obtained the Pharmaceutical Manufacturing License in October 2024. The production and quality meet the requirements of FDA, EMA, and NMPA. The telpopeptide API was successfully registered with the FDA in January 2025 (DMF filing). With a complex long-acting peptide modification and optimization service platform, it can produce more than 95% of customized synthetic peptide types on the market; provide full-process peptide CDMO/CMC services from drug screening (SAR), preclinical CMC, clinical samples to registration support, as well as CRO, CMO, and beauty peptide one-stop services. We have accumulated more than 35 years of industry cooperation experience, more than 1,000 cooperative customers, and 2 production bases.

Nortex Biotech (stock code 688076) focuses on polypeptide drugs and small molecule drugs, adopts the combination of independent R&D and custom R&D and production, and forms self-developed and customized two-wheel drive in the fields of advanced pharmaceutical intermediates, APIs and preparations. The company was established in Lianyungang in 2009 and listed on the Science and Technology Innovation Board in 2021. Its Hangzhou Aosino focuses on the R&D and production of new small molecule drugs, advanced intermediates and peptide fragments (Zhejiang Hangzhou R&D Center + Jiande GMP Commercialization Base). In terms of peptide APIs, there is a large production capacity of side chain chemically modified peptides and long chain modified peptides with a single batch of 10 kg or more, and the production capacity of peptide APIs has reached tonnage (expected to reach several tonnage by the end of 2025). A quality management system in line with USFDA/EDQM/NMPA has been established. The Lianyungang factory has successively passed the US FDA on-site inspection/flight inspection, South Korea MFDS, Brazil ANVISA and other inspections. The R&D team is led by experts such as the "100 Talents Program" of the Chinese Academy of Sciences, and provides CDMO/CMO services from advanced intermediates and APIs to preparations for innovative pharmaceutical companies around the world. It has R&D centers and production bases in Hangzhou/Lianyungang/Jiande and more than 2,000 employees.

Founded in 2013, Nanjing Jetpeptide Biotechnology Co., Ltd. (Jetpeptide Biotechnology) is an enterprise that integrates R&D, development and production of polypeptide reagents. The company can synthesize thousands of polypeptides of different sequences at the same time. It is equipped with a professional production team and equipment. From raw material procurement to final testing, each process is strictly controlled. The synthesis data, purification methods, quality inspection and mass spectrometry reports, and storage methods of each polypeptide are recorded in detail. It can provide research users and large enterprises with peptide products ranging from milligrams to kilograms and with the highest purity of 99%. It has supplied tens of thousands of active peptides to thousands of research users around the world. The products cover the whole country and are exported to Europe, the United States, the Middle East, Hong Kong, Macao and Taiwan. Complex modification capabilities include methylation, polyphosphorylation, head-tail cyclization, a variety of fluorescent labels, and book-linked peptides, and have successfully synthesized long peptides with more than 120 amino acid residues. Establish long-term cooperation with thousands of scientific research institutes, institutions and enterprises at home and abroad (including Baekje Shenzhou, Oxford University, National Protein Research Center, etc.), with legal import and export qualifications.

Active spot merchants on B2B platforms, sending overseas directly in small batches

Hefei Star Peptide Biotechnology Co., Ltd., located in Hefei, was established in 2021. It is a high-tech enterprise committed to the fields of life sciences and biotechnology. It mainly engages in polypeptide synthesis, polypeptide customization, polypeptide purification and other polypeptide preparation technology services (and also engages in small molecule customization synthesis). The company has an independent R&D center and aseptic laboratory of about 2000 square meters in Hefei High-tech Zone, and has built 4 complete polypeptide production lines, equipped with Waters LC-MS/MS, UPLC, automatic purifier, Shimadzu LCMS, automatic lyophilization system and other instruments, with a monthly production capacity of about 3000 high-quality polypeptides. The team consists of more than 100 people, including more than 10 doctors and masters. At the beginning of 2021, Hefei High-tech Zone and the Chinese Academy of Sciences signed a strategic investment agreement with them respectively. Position "Be an expert in peptide synthesis around you" to provide domestic and foreign universities and biomedical enterprises with development, amplification and batch customization services from mg to tonnage.

Hefei Peptide Library Biotechnology Co., Ltd. (Taikubio) is a high-tech enterprise committed to peptide synthesis research and peptide custom synthesis. The core team has a background in the chemical industry at home and abroad and rich R&D and management experience. The company has 1500 square meters of office/experimental space, equipped with precision instruments such as Waters LC-MS/MS, UPLC, automatic purifier, Shimadzu LCMS, and automatic lyophilization system; thousands of catalog peptides such as polypeptides/pet probe precursors are available in stock, and more than 400 kinds of modification and drug coupling technology routes are accumulated, which can undertake milligram to kilogram level production, covering the comprehensive needs of scientific research and customization and from small-scale trials, pilot trials to large-scale production. Mainly engaged in peptide API intermediates, cosmetic peptides, customized peptides, and HPLC purification and bioassay services; can be customized to produce pet probe precursors (FAPI, PSMA, polypeptides, NEB, etc.) and related intermediates. It has established cooperation with universities such as Peking University, Tsinghua University, Zhejiang University and foreign pharmaceutical companies.

Hefei Guopeptide Biotechnology Co., Ltd. is a high-tech enterprise located in Hefei High-tech Zone. It has been jointly expanded into a large-scale peptide synthesis base by a number of well-known peptide companies, integrating the customization and research and development of peptides and related products. The company adheres to "large brands, high-end quality, professional services", has a professional R&D team and advanced instruments and equipment, focuses on professional peptide synthesis customization services, and can provide customers with sequence chemistry and physical property analysis. Mastering the current advanced peptide synthesis and modification technology, it has successfully synthesized a long sequence of more than 120 amino acid residues, and the success rate of fluorescence, methylation, isotopes, biotin and other modifications is as high as 99%. The products cover all provinces and cities across the country, and are exported to Europe, the United States, the Middle East, Hong Kong, Macao, Taiwan and other countries and regions, maintaining long-term cooperation with many well-known universities, large pharmaceutical companies and research institutes.

Hefei HeSheng Biotechnology Co., Ltd. was established in 2014 and is located in Hefei High-tech Zone. It is an innovative polypeptide biotechnology company with polypeptide technology as its core. It focuses on the customization, research and development, production and service of polypeptide-related products, and is committed to becoming an international polypeptide CRDMO integrating polypeptide scientific research and customization, drug polypeptide intermediates and impurity customization, peptide API production, drug polypeptide research and development and process development, and beauty polypeptide research and development and production. The factory area of the company is about 4,000 square meters, and there are polypeptide R&D and production workshops such as synthesis, purification and analysis, with a total planned annual raw material production capacity of 200 kg (powder). It has more than 100 patents (including 24 invention patents). The service covers research custom polypeptide synthesis (long peptide, difficult peptide, branch peptide), labeling (isotope, fluorescence), cyclic peptide (amide ring, disulfide ring, subscription peptide ring, thioether ring), modification (glycopeptide, phosphorylation, peg, etc.), deuterated service, and polypeptide drug impurity customization; GMP small test/pilot and amplification production (mg to kg grade) can be carried out.

Founded in January 2018, Hefei Shengjing Peptide Biotechnology Co., Ltd. is a high-tech enterprise with peptide as its core. The founding team came from Tsinghua University and China University of Science and Technology. The company has created KPDS (KS-V Peptide Discovery Services Platform), a leading international peptide drug discovery platform, which provides pharmaceutical companies, biotechnology companies and scientific research units with one-stop, customized and strategic peptide discovery services. Business focuses on polypeptide drugs, nuclide conjugate drugs (RDCs), polypeptide drug conjugates (PDCs), multifunctional peptide conjugates, and disease diagnosis and health care functional products; specializes in the custom synthesis of difficult polypeptides (toxin peptides, ubiquitin and ubiquitin probes, modified histones and nucleosome assemblies), drug peptide transformation and optimization, polypeptide process development, and polypeptide library construction. The registered capital is about 41.5 million yuan, and the team size is about 50–99 people.

Founded in 2013 in Hefei, Cellmano Biotech Limited is a high-tech company focused on the research and industrialization of solid phase peptide synthesis methods. The company has been engaged in the R&D and manufacturing of solid-phase polypeptide synthesis since 2011. It has a R&D center that meets the requirements of solid-phase synthesis, lyophilization and purification, and a complete set of analytical and testing instruments. The synthesis records, purification methods and test reports of each batch of products are archived in detail. Its main business includes peptide intermediates, cosmetic peptides (cosmetic peptides), custom synthesis of peptides, and peptide CMO services. It can provide customized peptides from mg to kg, from crude to 98% purity, and establish more than 2,000 commonly used catalog peptides in stock (gradually improve inventory, deliver in as fast as one week) to serve customers around the world. Approximately 10–50 employees.

Founded in 2014, Hangzhou Go Top Peptide Co., Ltd. (Go Top Peptide) is a national high-tech enterprise focusing on the R&D and production of polypeptides and related derivatives. It is the governing unit of the polypeptide branch of the China Biochemical Pharmaceutical Industry Association. The company has more than 4,000 square meters of polypeptide research and development center in Hangzhou, and has established two commercial polypeptide production bases in Shangyu and Anji, Zhejiang. It has a number of polypeptide production lines, large-scale polypeptide synthesis equipment, imported HPLC analysis and preparation equipment, and is equipped with a GMP standard clean laboratory. It has passed ISO9001: 2015 quality management system certification. Provides peptide customization, modification, catalogue peptides and scientific/pharmaceutical peptide products.

Established in 2023, Hangzhou Beiputai Biopharmaceutical Co., Ltd. is a high-tech enterprise focusing on the R&D and sales of polypeptides and related derivatives. The company has established a polypeptide R&D center in the Overseas Student Entrepreneurship Park in Qiantang District, Hangzhou. It is equipped with several polypeptide R&D production lines and large-scale analytical equipment such as Agilent high-performance liquid chromatography and AB mass spectrometry. The R&D team has more than 10 years of polypeptide experience and can meet personalized customization. Products include GLP-1 polypeptides (Smeglutide, Tirpopeptide, Retalutide, etc.), small molecule mimetic peptides, radioimaging polypeptide precursors (RDC precursors, such as FAPI/PSMA/Oct), PDC polypeptides, polypeptide inhibitors (aldehyde peptides/FMK/CMK, etc.), luciferase substrates, glycopeptides, isotope-labeled peptides, macrocyclic polypeptides, maps complex antigen peptides, fluorescent labeled peptides, cell transmembrane peptides, etc. More than 100 mature polypeptides have been produced, with an annual output of more than 100 kg of polypeptides.

Hangzhou Mandy Biotechnology Co. Founded in April 2014,, Ltd. is a Chinese peptide product R&D, production and export enterprise, focusing on independent R&D, manufacturing and customization of peptide products, with strong R&D and quality control capabilities in the biomedical industry. With more than ten years of experience in polypeptide research and development, the company has established a strict quality control system to provide polypeptide products and customized solutions to scientific research institutions, pharmaceutical companies and biotechnology companies around the world.

Founded in 2000, Hainan Shuangcheng Pharmaceutical Co., Ltd. is a high-tech enterprise featuring chemically synthesized polypeptide drugs. It was listed on the Shenzhen Stock Exchange (stock code 002693) in August 2012 and specializes in the research and development, production and sales of chemically synthesized polypeptide drugs. The company has formed a mature technical system in the synthesis, purification, analysis, quality assurance, activity determination and preparation process of polypeptides. It has successfully developed a number of chemically synthesized polypeptides such as thymosin for injection ("Kitai"), somatostatin for injection, bivalirudin for injection, and etibatin injection. Among them, the thymosin method has passed the consistency evaluation and has been approved by the Italian market, and bivalirudin and etibatin anda have been approved by the US FDA. The marketing network covers more than 30 provinces and cities in China, more than 600 pharmaceutical manufacturers, and more than 10,000 hospital terminals. The company is strategically positioned to become a major global supplier of peptide APIs and a major producer of peptide generic pharmaceutical formulations.

Harbin Jixianglong Biotechnology Co., Ltd. was established at the end of 2011 and is located in the Harbin Limin Development Zone. It covers an area of 23,000 square meters, 16,000 square meters of buildings, a registered capital of 18.31 million yuan, a net asset of 110 million yuan, and 260 employees (70 R&D). It is a national high-tech enterprise, Heilongjiang Specialized New SME and Synthetic Peptide Drug Technology Innovation Center. The company focuses on independent R&D and custom R&D and production of peptide drugs, forming a two-wheel drive pattern of peptide raw material sales and formulation R&D services (CRO). It has built a GMP-certified peptide raw material production workshop, equipped with more than 300 sets of equipment such as solid phase synthesizers, preparation liquid chromatography, lyophilizers, and HPLC. The company has a complete industrial chain of R&D, approval and production, and has obtained 10 API production approvals (the third in the country in terms of quantity) using its own technology; Smeglutide and Tirpotide have completed US DMF filings with the US FDA and obtained NDCs for sale in US pharmacies; it has 16 invention patents (including 5 compound patents).

1688 spot order supplier, suitable for trial order purchase

Fujian Genohope Biotech Co., Ltd. (Genohope Biotech) was co-founded by the World's Top 500 New Hope Group and Taiwan's well-known peptide company Genovior (now part of Polaris Pharma Group). It is located in the Biological and New Pharmaceutical Industry Zone on both sides of Putian, Fujian, and is positioned as a global R&D and production center for polypeptide products. The company has more than 20 years of industry experience, a team of more than 500 people, covering more than 50 countries, organized according to GMP specifications, equipped with glass reactors, freeze-drying lines, automatic filling lines and other equipment. HP Peptide API products cover GLP/polypeptide products such as tilbopeptide, smectin, tidoglutide, itecarbide, mastopeptide, lanrein acetate, and oral sterile water for injection. We provide peptide API supply and services to customers around the world.

Seno Biotechnology is a "specialized specialty" and national high-tech enterprise focusing on the field of polypeptides. It was listed in 2021 and integrates R&D, production and sales. Its business covers polypeptide APIs, cosmetic active peptides, CDMO services and polypeptide preparations. It is a leader in the field of polypeptide APIs in China and has a full industrial chain capability from drug discovery to commercial production. The core team has more than 15 years of peptide synthesis research and practical experience. Peptide API production capacity of 1.5 tons, single batch production of up to kg, master more than 50 domestic and foreign marketed peptide production of large-scale key technologies, products covering the digestive system, immune system, anti-tumor, chronic hepatitis B, diabetes and obstetrics and other therapeutic areas, a variety of products have passed the multi-national certification.

Sinopep-Allsino Biopharmaceutical is a global supplier of commercial grade APIs and a full range of polypeptide/oligonucleotide CDMOs. Providing end-to-end CMC development and cGMP production from early R&D to commercialization for new drugs (NCE) and innovative pharmaceutical companies since 2009. The company's current production capacity of polypeptides is about 20–30 tons/year. It has built a large-scale GMP oligonucleotide (ASO, siRNA and GalNAc, AOC, liposome and other conjugates) production facility that can produce thousands of kilograms per year in Lianyungang, Jiangsu Province. At the same time, it has small molecule generic drugs and NCE commercial production capacity. The quality and regulatory system is mature. It has passed four FDA on-site inspections, strictly follows FDA and ich guidelines, and provides process development, analytical method development and verification, stability research, and global IND/NDA declaration support.